474 related articles for article (PubMed ID: 30458443)
21. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Azanza JR; Grau S; Vázquez L; Rebollo P; Peral C; López-Ibáñez de Aldecoa A; López-Gómez V
Mycoses; 2021 Jan; 64(1):66-77. PubMed ID: 32989796
[TBL] [Abstract][Full Text] [Related]
23. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
[TBL] [Abstract][Full Text] [Related]
24. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
25. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
[TBL] [Abstract][Full Text] [Related]
26. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
[TBL] [Abstract][Full Text] [Related]
27. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
Hoenigl M; Prattes J; Neumeister P; Wölfler A; Krause R
Mycoses; 2018 Mar; 61(3):201-205. PubMed ID: 29112326
[TBL] [Abstract][Full Text] [Related]
28. Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.
Lahmer T; Batres Baires G; Heilmaier M; Schmid RM; Sörgel F; Kinzig M; Huber W; Mayr U; Rasch S
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427296
[TBL] [Abstract][Full Text] [Related]
29. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Shirley M; Scott LJ
Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
[TBL] [Abstract][Full Text] [Related]
30. Quantification of Serum Voriconazole, Isavuconazole, and Posaconazole by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).
Smith A; Dowis J; French D
Curr Protoc Toxicol; 2018 May; 76(1):e47. PubMed ID: 30040225
[TBL] [Abstract][Full Text] [Related]
31. A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.
Decembrino N; Perruccio K; Zecca M; Colombini A; Calore E; Muggeo P; Soncini E; Comelli A; Molinaro M; Goffredo BM; De Gregori S; Giardini I; Scudeller L; Cesaro S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871077
[TBL] [Abstract][Full Text] [Related]
32. [Invasive aspergillosis in solid organ transplantation].
Silva JT; Torre-Cisneros J; Aguado JM
Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
[TBL] [Abstract][Full Text] [Related]
33. New Perspectives on Antimicrobial Agents: Isavuconazole.
Lewis JS; Wiederhold NP; Hakki M; Thompson GR
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0017722. PubMed ID: 35969068
[TBL] [Abstract][Full Text] [Related]
34. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
[TBL] [Abstract][Full Text] [Related]
36. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
37. Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation.
Oarbeascoa G; Dorado N; Bailén R; Serrano D; Balsalobre P; Pradillo V; Guinea J; Padilla B; Sancho M; Machado M; Buño I; Anguita J; Diez-Martin JL; Kwon M
Chemotherapy; 2019; 64(2):57-61. PubMed ID: 31484176
[TBL] [Abstract][Full Text] [Related]
38. Validation of an Isavuconazole High-Performance Liquid Chromatography Assay in Plasma for Routine Therapeutic Drug Monitoring Applications.
Mueller SC; Karasch I; Lakner J; Wacke R
Ther Drug Monit; 2018 Aug; 40(4):503-506. PubMed ID: 29994987
[TBL] [Abstract][Full Text] [Related]
39. Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.
Jović Z; Janković SM; Ružić Zečević D; Milovanović D; Stefanović S; Folić M; Milovanović J; Kostić M
Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):139-157. PubMed ID: 30284178
[TBL] [Abstract][Full Text] [Related]
40. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
Guinea J; Bouza E
Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
